Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 May 1;23(9):2187-94.
doi: 10.1016/j.bmc.2015.02.057. Epub 2015 Mar 6.

Design, synthesis and biological evaluation of a highly-potent and cancer cell selective folate-taxoid conjugate

Affiliations

Design, synthesis and biological evaluation of a highly-potent and cancer cell selective folate-taxoid conjugate

Joshua D Seitz et al. Bioorg Med Chem. .

Abstract

The folate receptor (FR) has been widely recognized as an excellent target for the tumor-selective delivery of cytotoxic agents, and four folate-drug conjugates have entered clinical evaluations for the treatment of solid tumors to date. However, most of these conjugates required structural modification of the cytotoxic warheads in order to achieve efficient drug release from the linkers. We designed and constructed a novel folate conjugate of a highly-potent next-generation taxoid, SB-T-1214, by exploiting bioorthogonal Cu-free 'click' chemistry. The synthesis was highly convergent and required no HPLC purification to obtain the final folate-taxoid conjugate 1. Conjugate 1 demonstrated highly FR-specific potency (IC₅₀ 2.1-3.5 nM) against a panel of cancer cell lines, with a >1000-fold decrease in cytotoxicity against normal human cells (IC₅₀>5000 nM). The remarkable potency and selectivity of conjugate 1 can be attributed to highly FR-specific receptor-mediated endocytosis as well as efficient release of the unmodified cytotoxic warhead using a mechanism-based self-immolative linker.

Keywords: Anticancer agent; Drug conjugate; Folic acid; Taxoid; Tumor-targeted.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mechanism of the self-immolative disulfide linker.
Figure 2
Figure 2
Retrosynthetic analysis for the folic acid conjugate of next-generation taxoid SB-T-1214 (1)
Scheme 1
Scheme 1
Synthesis of folyl(dipeptide)-PEG-azide 2 Reagents and Conditions: a) 11-azido-3,6,9-trioxa-11-undecan-1-amine, EDC·HCl, CH2Cl2, 83%; b) TFA, CH2Cl2, 98%; c) piperidine, DMF; d) 5, HOBt, HBTU, DMF; e) piperidine, DMF; f) Fmoc-Glu(OH)-OtBu, HOBt, HBTU, DMF; g) piperidine, DMF; h) N10-TFA-pteroic acid, HOBt, HBTU, DMF; i) TFA, TIPS, H2O, 56%; j) NH4 OH, H2O, quant.
Scheme 2
Scheme 2
Synthesis of amino-PEG3-cyclooctyne 11 Reagents and Conditions: a) LiOH, H2O, dioxane, 50 °C, 91%; b) NHS, DIC, DMAP, CH2Cl2, 83% c.) 4,7,10-trioxa-1,13-tridecanediamine, CH2Cl2, 73%.
Scheme 3
Scheme 3
Synthesis of folate-taxoid conjugate 1

Similar articles

Cited by

References

    1. Siegel R, Ward E, Brawley O, Jemal A. CA: Cancer J Clin. 2011;61:212. - PubMed
    1. Ojima I, Chen J, Sun L, Borella C, Wang T, Miller M, Lin S, Geng X, Kuznetsova L, Qu C, Gallager D, Zhao X, Zanardi I, Xia S, Horwitz S, Clair JMS, Guerriero J, Bar-Sagi D, Veith J, Pera P, Bernacki R. J Med Chem. 2008;51:3203. - PMC - PubMed
    1. Ojima I. Acc Chem Res. 2008;41:108. - PubMed
    1. Botchkina G, Zuniga E, Das M, Wang Y, Wang H, Zhu S, Savitt A, Rowehl R, Leyfman Y, Ju J, Shroyer K, Ojima I. Mol Cancer. 2010;9:192. - PMC - PubMed
    1. Chen S, Zhao X, Chen J, Chen J, Kuznetsova L, Wong S, Ojima I. Bioconjugate Chem. 2010;21:979. - PMC - PubMed

Publication types